At the time of recruitment for this study, third-generation aromatase inhibitors (AIs) were the treatment of choice for postmenopausal women with newly diagnosed metastatic oestrogen receptor (ER)-positive breast cancer, either in tamoxifen-naïve patients or those progressing on adjuvant tamoxifen. The gene discussed is CYP19A1; the disease is breast cancer.